Wright Chadwick L, Maly Joseph J, Zhang Jun, Knopp Michael V
Wright Center of Innovation in Biomedical Imaging, Division of Imaging Science, Department of Radiology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Room 430, Columbus, OH 43210, USA.
Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Starling Loving Hall 406C, 320 West 10th Avenue, Columbus, OH 43210, USA.
PET Clin. 2017 Jan;12(1):63-82. doi: 10.1016/j.cpet.2016.08.005. Epub 2016 Oct 6.
PET with fluorodeoxyglucose F 18 (F FDG-PET) is a meaningful biomarker for the detection, targeted biopsy, and treatment of lymphoma. This article reviews the evolution of F FDG-PET as a putative biomarker for lymphoma and addresses the current capabilities, challenges, and opportunities to enable precision medicine practices for lymphoma. Precision nuclear medicine is driven by new imaging technologies and methodologies to more accurately detect malignant disease. Although quantitative assessment of response is limited, such technologies will enable a more precise metabolic mapping with much higher definition image detail and thus may make it a robust and valid quantitative response assessment methodology.
使用氟脱氧葡萄糖F 18（F FDG-PET）的正电子发射断层显像（PET）是用于淋巴瘤检测、靶向活检和治疗的一种有意义的生物标志物。本文回顾了F FDG-PET作为淋巴瘤假定生物标志物的发展历程，并探讨了当前在淋巴瘤精准医疗实践方面的能力、挑战和机遇。精准核医学由新的成像技术和方法推动，以更准确地检测恶性疾病。尽管对反应的定量评估有限，但此类技术将实现更精确的代谢图谱绘制，图像细节清晰度更高，因此可能使其成为一种可靠且有效的定量反应评估方法。
